expect currenc neg impact ep think
off-set roughli half lead us lower ep estim given
consist strength sale growth upsid model sale
libr mitraclip driver optimist navig currenc
well-round quarter offer optim oper outlook
abt revenu total vs street expect revenu improv
organ basi beat street forecast essenti match
organ sale growth compani post despit meaning tougher year-
over-year comparison face four straight quarter shown stellar organ
sale growth exceed achiev growth three four quarter
nutrit sale surpass street consensu repres
organ growth pediatr nutrit deliv balanc growth infant toddler
categori along above-market growth double-digit intern growth
adult nutrit benefit strength ensur glucerna brand well robust
intern growth diagnost sale fell modestli short street
forecast though organ growth vs last quarter alin growth
acceler due competit win europ manag note greater
instrument placement result share captur manag expect posit
trend alin persist above-market growth sever year back
share expans avail system addit market includ
 rapid diagnost acquir late last year gener sale thank
strong revenu growth cardiometabol test epd sale total
street expect organ sale growth epd
result propel double-digit growth sever market russia china
although tough comp india channel restock repres modest headwind
sale medic devic exceed consensu forecast vs
organ continu recent strength shown divis medic devic
franchis benefit except perform electrophysiolog
structur heart led double-digit growth heart map ablat confirm
ep within structur heart double-digit growth amplatz pfo mitraclip
growth diabet sale total world-wide libr sale
repres organ growth gross margin
exceed street project well compani guidanc gross
margin around
adjust ep came match street estim top abt
guidanc rang along result refin full-year ep
guidanc vs prior guidanc keep midpoint
unchang compar street consensu manag also
issu ep guidanc compar consensu
pleas see page report import disclosur
spin-out proprietari pharma new redux pre-humira
larg diversifi medic product compani competit global franchis
nutrit diagnost medic devic intern brand gener pharmaceut
post-spin ad st jude medic aler busi divest
advanc medic optic unit next five year believ combin abt/stj/
alr busi pois deliv revenu growth ep growth low mid-
teen make standout perform compar medic devic peer believ
may upsid estim potenti out-performance busi unit
better-than-expect contribut stj pipelin product success business-
develop initi blend valuat analysi dcf sum-of-the-part price-to-earnings
support outperform rate expect share outperform market
increas market adopt mitraclip
gross oper margin expans
next five year
 enhanc product
acceler diagnost unit
persist emerg market headwind
nutrit
stronger stj synergi captur alr
acceler recoveri intern
hsd revenu mid-dd ep growth
franchis four major health care segment one diversifi
large-cap medic devic compani world offer lead product
nutrit diagnost medic devic establish brand gener pharmaceut
approxim compani revenu gener unit state
anoth come western europ canada japan australia remain
emerg market includ india china russia brazil januari
complet separ proprietari research-bas pharmaceut busi
oper independ large-cap pharmaceut compani
guidanc set reason bar room upsid
provid detail fourth quarter full-year outlook compani
narrow ep guidanc prior rang
fourth quarter guid mid- high-single-digit organ growth
currenc headwind report sale manag expect diagnost
sale fourth quarter epd organ growth mid-singl digit nutrit growth
low- mid-singl digit diagnost growth mid- high-singl digit medic
devic growth high-singl digit
outlin full-year gross margin target sale indic increment
improv busi target full-year adjust
sg expens target look see adjust ep rang
think achiev base compani organ sale growth
guidanc mid- high-singl digit specif forecast futur growth driver like libr
provid made point mention critic new product success
overal busi recent coapt trial discuss plan
submit studi fda come week help support
fmr indic mitraclip although estim provid futur mitraclip
sale mention medic devic sale like grow high-singl
digit reflect double-digit growth sever area busi like impli
structur heart beneficiari increas sale mitraclip next sever
reflect abt earn call view result suffici support
bull case share especi given numer near-term growth driver play
notabl libr mitraclip biggest overhang guidanc impact
exchang rate discuss length call acknowledg risk
currenc pose state current rate compani anticip exchang
neg impact report sale
revis ep greater currenc impact remain bullish
wednesday confer call manag twice ask confid
deliv double-digit low teen earn growth task made harder
currenc headwind compani face manag call currenc eleph
room rightli said problem multi-national compani time
want commit project far currenc headwind continu
indic rate remain current level earn impact
would like cent respons question
achiev earn growth project street current ep
consensu repres growth midpoint abt ep
guidanc manag indic would start assumpt bless
street assum sinc answer distinctli differ one given
question near-term sale manag said convict sale
growth north expect year-over-year ep growth
becom start point new consensu calcul lower
ep forecast ep estim previous
importantli assum off-set half currenc headwind face
lead us model half aforement impact year
see neg chang compani underli earn growth
chang multipl rang use valuat price target remain
reiter outperform rate
compani report thomson eikon cowen compani
consensu chg establish lab molecular poc medic cv rhythm manag heart structur diabet good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper dilut share compani report cowen compani estimatesour estimatesactu cowen
compani report thomson eikon cowen compani
consensu chg pharma nutrit ww nutrit ww nutrit ww cardiovascular neuromodul ww rhythm manag ww electrophysiolog ww heart failur ww vascular ww structur heart ww neuromodul ww ww diagnost ww diagnost ww diagnost ww compani report cowen compani estim actualsour estimatesabt quarterli revenu highlight mm cowen
compani report thomson eikon cowen compani
good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper restructur non-recur charg dilut share analysisgross end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
laboratori diagnost laboratori diagnost molecular diagnost point diagnost point diabet revenu rhythm manag heart failur rhythm manag heart cardiovascular structur heart cardiovascular structur revenu end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
adjust good adjust gross adjust gross oper incom oper incom interest expens interest net interest expens currenc hedg loss expens net expens pre-tax incom incom tax incom tax net incom adj net incom oper net incom oper ep continu oper ep discontinu oper changeadjust ep oper includ disc ep oper share analysisgross incom -oper cowen
compani report thomson eikon cowen compani
 exclud ww sale exclud pharma exclud exclud ww sale exclud devic tradit exclud ww tradit ww sale exclud atrial fibril exclud ww atrial ww sale exclud heart failur exclud ww heart ww sale exclud rhythm manag heart failur exclud ww rhythm manag heart ww sale exclud vascular exclud ww ww sale exclud structur heart exclud ww ww sale exclud cardiovascular structur heart exclud ww ww sale exclud neuromodul exclud ww ww sale exclud neuromodul exclud ww stj ww sale exclud diabet exclud ww diabet ww sale exclud revenu exclud ww ww sale exclud total revenu exclud ww sale exclud total revenu pro-forma stj alr exclud ww sale exclud cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
risk includ stj alr integr global competit pressur adult
pediatr nutrit busi price pressur procedur volum pressur
stent busi vascular product regulatori time approv mitraclip
 risk time regulatori approv meet demand
hundr product launch emerg market establish pharmaceut
busi meet growth target develop emerg market
meet target margin improv four major segment
